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Abstract High-density lipoprotein (HDL) remodeling
within the plasma compartment and the association
between lecithin-cholesterol acyltransferase (LCAT) and
cholesterol ester transfer protein (CETP) activity, and lipid,
lipoprotein concentrations and composition were investi-
gated. The aim was to examine the high sensitivity of
C-reactive protein (hsCRP), lipid, apolipoprotein B (apoB),
apoAI, total apoAII, apoAIInonB, apoB-containing apoAII
(apoB:AII), total apoCIII, apoCIIInonB, apoB-containing
apoCIII (apoB:CIII) concentration and LCAT and CETP
activity to gain an insight into the association between
them and LCAT and CETP, 57 post-renal transplant (Tx)
patients with and without statin therapy and in 15 healthy
subjects. Tx patients had moderate hypertriglyceridemia,
hypercholesterolemia, and dyslipoproteinemia, disturbed
triglyceride-rich lipoproteins (TRLs) and HDL composi-
tion, decreased LCAT, and slightly increased hsCRP but no
CETP activity. Spearman’s correlation test showed the
association between lipids and lipoproteins and LCAT or
CETP, and multiple ridge stepwise forward regression
showed that immunosuppressive therapy in Tx patients can
disturb HDL and TRLs composition. The results suggest
that inhibition or activation of LCAT is due, in part, to
HDL-associated lipoprotein. Lipoprotein composition of
apoAI, apoAIInonB, and apoCIIInonB in HDL particle and
apoB:AII TRLs can contribute to decrease LCAT mass in
Tx patients. Tx patients without statin and with lower tri-
glycerides but higher HDL cholesterol concentration and
disturbed lipoprotein composition of ApoAI and apoAII in
HDL particle can decrease LCAT, increase LDL choles-
terol, aggravate renal graft, and accelerate atherosclerosis
and chronic heart diseases.
Keywords Apolipoprotein (apo)AI  apoB  apoAII 
apoAIInonB  apoB-containing apoAII  apoCIII 
apoCIIInonB  apoB-containing apoCIII  LCAT  CETP 
hsCRP  Renal transplant
Introduction
Lecithin-cholesterol acyltransferase (LCAT) is a plasma
enzyme that esterifies cholesterol and raises high-density
lipoprotein cholesterol (HDL-C). Cholesteryl esters (CE)
are significantly more hydrophobic than free cholesterol
and are formed by LCAT partition from the surface of
lipoprotein to the hydrophobic core. This transforms the
small pre-b HDL into larger, spherical-shaped a-migrating
forms of high-density lipoprotein (HDL). The increase in
size of the HDL stabilizes it from removal by renal clear-
ance. LCAT prevents the reverse exchange of cholesterol
by passive diffusion from HDL to the peripheral cells and
also promotes net removal of cholesterol from the periph-
eral cells to the HDL [1, 2]. After cholesterol esterification
by LCAT, the cholesteryl esters on the HDL are transferred
to apoB-containing lipoproteins by cholesteryl ester trans-
fer protein (CETP), although approximately 25 % of cho-
lesteryl esters are directly formed on apoB-containing
lipoproteins. The cholesteryl esters are delivered to the
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liver for excretion, either by the uptake of low-density
lipoprotein (LDL) by the LDL receptor, or by selective
lipid uptake by scavenger B receptor type I (SB-BI) in the
liver [2–5]. LCAT is a key factor in promoting the for-
mation of the HDL particle containing apoAI and apoAII
by fusion of the spherical a-HDL-containing apoAI and
nascent discoid HDL-containing apoAII. Distribution of
HDL apolipoproteins, which are exchangeable, is modified
by LCAT, CETP, phospholipid transfer protein (PLTP) and
hepatic lipase. The HDL structural remodeling and apoAI
dissociation are essential for reversing cholesterol transport
(RCT) [2, 6]. LCAT is an enzyme in the HDL metabolism
and RCT and may play an important role in modulating
plasma triglycerides (TG) levels, but the underlying
mechanism has not been explored nor has the association
with apoCIII, apoCIIInonB, apoB-containing apoCIII
(apoB:CIII); apoAII, apoAIInonB, apoB-containing apoAII
(apoB:AII); and lipids [7]. Its role in human atherosclerosis
in post-renal transplant patients (Tx) with chronic kidney
disease has not been definitively established and is likely
to be context dependent [8]. Studies have produced con-
flicting results for the anti- or pro-atherogenic role of
LCAT [9–11]. Therefore, the exact role of LCAT in the
pathogenesis of atherosclerosis is still not fully known.
Unfortunately, there is no information about the association
between LCAT and CETP activity, and the concentration
and composition of lipoprotein HDL and triglyceride-rich
lipoproteins (TRLs) metabolism in Tx patients without
active inflammatory.
The aim of the present study was to examine hsCRP,
lipids, apoB, apoAI, total apoAII, apoAIInonB, apoB:AII,
total apoCIII, apoCIIInonB, apoB:CIII concentration, and
LCAT and CETP activity to gain an insight into the
association between them and LCAT and CETP in 57 Tx




A total of 57 post-renal transplant patients (Tx) (28 males
and 29 females) aged 19–66 years and 15 apparently nor-
molipidemic healthy individuals as controls were recruited
for the study. The Tx patients had undergone treatment in
the Nephrology Department of the Medical University in
Lublin. These patients did not have proteinuria, active
inflammatory disease, liver disease, malignancy or diabetes
mellitus, but did have hypertension (n = 38) and cardio-
vascular disease (n = 1). The causes of kidney disease in
the post-renal transplant patients were the following: glo-
merulonephritis in 48 patients, interstitial nephritis in 7,
and unknown in 2. The Tx patients with hypertension were
using anti-hypertensive medications of either calcium
channel blockers or angiotensin-converting enzyme
antagonists, angiotensin II receptor subtype 1 (AT1)
blockers and a-blockers, but no diuretics were used in any
of the studied groups. The number of hyperlipidemic
patients treated with atorvastatin or simvastatin is 25
(n = 25), but 32 Tx patients did not receive statin therapy.
All Tx patients on immunosuppressive treatment received
calcineurin inhibitors and prednisone. Statin-treated
patients received mainly cyclosporine (60 % of Tx
patients). In this group, the Tx patients received
CSA ? Myfortic, CSA ? Azatiopryne, and CSA ? Cell-
Cept; the patients were given CSA, and Prograf ? My-
fortic and Prograf ? CellCept and CellCept ? Myfortic.
Tx patients without satin therapy received mainly prograf
(60 % of Tx patients) along with Myfortic, CellCept and
CSA ? Myfortic, together with CSA ? Azatiopryne and
CSA ? CellCept. One person received only prednisone.
All Tx patients were divided into three groups: all patients,
those with statin therapy, and those without. In patients
without statin group, those who had lower TG and higher
HDL C concentrations were selected.
The study was conducted in accordance with the
guidelines of the Ethics Committee of the Medical Uni-
versity in Lublin, Poland.
Detection of Lipids, Lipoproteins, hsCRP, and Routine
Laboratory Parameters
Lipids, lipoproteins, and routine laboratory parameters
were obtained in serum after a 14-h overnight fasting.
Blood was taken from vein and transferred to commercial
test tubes. Serum was immediately separated and stored in
aliquots at -80 C until use. Using routine laboratory
parameters, the level of creatinine and lipid was measured
on a Siemens analyzer (Germany). Low-density lipoprotein
cholesterol (LDL-C) was calculated according to the
Friedewald’s formula [12]. Non-HDL-C was calculated as
total cholesterol (TC) minus HDL-C. Lipoproteins apoAI,
apoB, and high-sensitivity C-reactive protein (hsCRP)
were determined with immunonephelometric methods,
using the Health Care Diagnostic Product (Siemens GmbH,
Germany) on a Dade Behring nephelometer BNII System
(Germany). Triglyceride-rich lipoproteins (apoB:CIII and
apoB:AII) were separated as non-HDL lipoproteins using
anti-apoB antibodies of Tx patients and healthy subjects.
Total apoCIII and apoCIIInonB were measured by elec-
troimmunodiffusion, according to Laurell, using a com-
mercial kit (Sebia, USA), and total apoAII and apoAIInonB
were measured with immunonephelometric methods, using
Siemens Health Care Diagnostic Product on a Dade Beh-
ring nephelometer BNII System. ApoB:AII was calculated
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as total apoAII minus apoAIInonB. ApoB:CIII was calcu-
lated from the difference between the total apoCIII and
apoCIIInonB.
Detection of LCAT and CETP Activity
A serum CETP assay kit (BioVision Inc., CA, USA), using
a donor molecule containing a fluorescent self-quenched
neutral lipid was transfererred to an acceptor molecule
results in fluorescence (Excitation: 465 mn; Emission:
535 nm). Serum LCAT assay kit (ELISA, Life Inc.,
Wuhan, China) was used. The kit is a sandwich enzyme
immunoassay for the in vitro quantitative measurement of
human LCAT in serum. The microtiter plate provided in
this kit had been pre-coated with an antibody specific to
LCAT. Standards or samples are then added to the
appropriate microtiter plate wells with a biotin-conjugated
polyclonal antibody preparation specific for LCAT. Next,
avidin in conjunction with horse radish peroxidase (HRP)
was added to each well. Only those wells that contained
LCAT, biotin-conjugated antibody and enzyme-conjugated
avidin exhibited a change color. The enzyme-substrate
reaction was terminated by the addition of a sulfuric acid,
and the color change was measured spectrophotometrically
at a wavelength of 450 nm ± 10 nm. The LCAT mass
(U/L - 1 lmol/min/L = amount of enzyme that catalyzes
the reaction of 1 lmol of substrate per minute under
standard conditions) activity in the samples was then
determined by comparing the O.D. of the samples to the
standard curve.
Statistical Analysis
The data were expressed as medians and minimum–maxi-
mum. Statistical analysis of the results obtained was per-
formed using the nonparametric Kruskal–Wallis test for
comparison of Tx patients groups and the controls. The
variables with skewed distribution were log-10-trans-
formed. However, the values in tables are presented as non-
transformed data. The relation between CETP or LCAT
activity and concentration of lipid, lipoprotein and lipid
and lipoprotein ratios were examined by Spearman’s cor-
relation analysis. Multiple ridge stepwise forward regres-
sion analysis was used to investigate the relationship
between LCAT as dependent variable and lipids, apoAI,
apoB, apoCIII, apoCIIInonB, B:CIII, apoAII, apoAIInonB,
apoB:AII, hsCRP concentrations, and CETP activity as
non-dependent variable. In the model of multiple regres-
sion analysis, high correlations between predictor variables
result in inadequate regression coefficients. In such cases,
multiple ridge stepwise forward regression analysis
improves the accuracy of the model. In the model of
multiple ridge forward stepwise regression analysis, LCAT
was selected as the dependent variable and lipoproteins as
the non-dependent variable, and for each of the non-
dependent variables, parameters were calculated according
to the equation: y = b0 ? b1x1 ? b2x2 ? … ? bnxn. The
relationship between the dependent variables is expressed
by the coefficient of multiple regression (b), which pro-
vides information about the relationship between the
dependent LCAT and the non-dependent variables. After
adjustment for age and gender, multiple ridge stepwise
forward regression analyses were performed in Tx patients.
The statistical significance of all variables was established
at P \ 0.05, and statistical analysis was performed using
the Statistica programme (StatSoft, Krakow, Poland).
Results
Table 1 presents the results of the clinical and labora-
tory parameters of Tx patients and the reference group.
Concentration of serum lipids (TG, TC, LDL-C, HDL-C,
non-HDL-C), lipoproteins (apoAI, apoB, total apoAII, apo-
AIInonB, apoB:AII, total apoCIII, apoCIIInonB, apoB:CIII),
hsCRP, LCAT and CETP activity, and lipid (TC/HDL-C,
LDL-C/HDL-C, TG/HDL-C) and lipoprotein (HDL-C/apoAI,
apoAI/apoB, apoAI/apoCIII) ratios in Tx patients with and
without statin therapy is given in Table 2. The in vivo results
of the present study show that Tx patients with and without
statin therapy had moderate hypertriglyceridemia, hyper-
cholesterolemia, dyslipoproteinemia, and atherogenic lipid
and lipoprotein ratios, decreased LCAT mass, and slightly
increased hsCRP, but no CETP activity. However, Tx
patients with statin therapy had a higher concentration of
LDL-C, apoB, and triglyceride-rich lipoproteins (TRLs-
apoB:CIII, apoB:apoAII) and lipid ratios, but lower con-
centration of HDL-C and lipoprotein ratios than Tx patients
without statin and the reference group.
Spearman’s correlation test (Table 3) for Tx patients with
statin therapy showed a significant positive correlation
between LCAT and apoCIIInonB and a significant negative
correlation between LCAT and TG level, and CETP activity
had a significant negative correlation with HDL-C level,
HDL-C/apoAI and apoAI/apoB ratios. However, Tx patients
without statin showed a significant positive correlation
between LCAT and apoB and apoCIII, and CETP activity
showed a significant positive correlation with HDL-C/apoAI
ratio. All Tx patients showed a significant positive correla-
tion between LCAT and apoB, apoCIII, apoCIIInonB, and
hsCRP concentration, and a significant negative correlation
with apoAI/apoB and apoAI/apoCIII ratios.
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Multiple ridge stepwise forward regression analysis in
all Tx patients (Table 4) showed that LCAT (R2 = 0.321)
as a dependent variable was associated positively with total
apoCIII (b = 0.368, P = 0.002) and negatively with TG
level (b = -0.306, P = 0.007). The group of selected Tx
patients with statin showed a significant negative associa-
tion between LCAT (R2 = 0.261) and TG concent-
ration (b = -0.415, P = 0.041). However, in Tx patients
without statin therapy, LCAT (R2 = 0.372) showed a sig-
nificant positive association with apoAII (b = 0.411,
P = 0.006) and a significant negative association with TG
(b = -0.492, P = 0.002) concentration. Moreover, in Tx
patients without statin therapy and with lower TG
(114(76–128) and higher HDL-C levels (56.9(43–74.7),
LCAT (R2 = 0.394) showed a significant positive associ-
ation with apoAII (b = 0.525, P = 0.018), a significant
Table 2 Concentration of lipids, lipoproteins, lipid and lipoprotein ratios, hsCRP, LCAT and CETP activity in the reference group and in post-
renal transplant patients (Tx) with and without statins
Reference group
(n = 15)
Tx patients with statin
(n = 25)
Tx patients without statin
(n = 32)
All Tx patients (n = 57)
TG (mmol/L) 0.98 (0.45–0.85) 1.39 (1.05–2.37)** 1.35 (0.73–1.88)** 1.38 (0.73–2.37)**
TC (mmol/L) 4.60 (3.55–4.82) 5.18 (3.42–6.16) 5.05 (3.60–5.90) 5.08 (3.42–6.16)
LDL-C (mmol/L) 2.22 (1.19–2.59) 3.37 (2.05–4.56)* 3.16 (1.35–4.45) 3.26 (1.35–4.56)
HDL-C (mmol/L) 1.79 (1.56–2.02) 1.11 (0.77–1.71)* 1.30 (0.90–1.93) 1.28 (0.77–1.93)
nHDL-C (mmol/L) 2.82 (1.56–2.02) 4.04 (2.64–5.30) 3.70 (2.43–4.92) 3.83 (2.83–5.30)
apoAI (mg/L) 1690 (1540–2660) 1570 (1010–2113) 1551 (1257–1973) 1560 (1001–2113)
apoB (mg/L) 690 (550–670) 989 (599–1558)* 832 (510–1151) 860 (510–1550)
apoAII (mg/L) 292 (246–354) 322 (179–498) 322 (243–436) 324 (179–498)
apoAIInB (mg/L) 288 (28.2–341) 254 (181–396) 253 (182–376) 254 (180–396)
apoB:AII (mg/L) 4 (2–52) 68 (20–134)** 66 (23–121)** 67 (20–134)*
hCRP (mg/L) 0.026 (0.016–0.20) 0.159 (0.030–1.90)*** 0.08 (0.016–5.22)*** 0.108 (0.016–5.2)***
apoCIII (mg/L) 28 (27–41) 52 (23–74)* 39 (18–59) 41 (18–74)
apoCIIInB (mg/L) 25 (23–36) 40 (15–59) 31 (14–50) 31 (14–59)
apoB:CIII (mg/L) 3.0 (2.5–8.0) 12 (25–26)* 8 (15–19.0) 10 (15–26)*
LCAT (U/L) 360 (66–450) 237 (125–390)* 180 (66–250)* 207 (66-390)*
CETP (pmol/lL/h) 48 (47–52) 48 (41–62) 49 (41–64) 48 (42–64)
TC/HDL-C 2.54 (1.79–2.67) 4.42 (2.94–7.13)*** 3.59 (2.36–6.42)*** 4.10 (2.36–7.13)***
LDL-C/HDL-C 1.24 (0.612–1.47) 2.70 (1.57–5.20)*** 2.20 (1.11–4.00)*** 2.44 (1.11–5.21)***
TG/HDL-C 1.26 (0.52–1.08) 2.94 (1.50–4.64)*** 2.35 (1.10–7.14)*** 2.50 (1.11–7.14)***
HDL-C/apoAI 0.40 (0.28–0.44) 0.29 (0.20–0.42)*** 0.31 (0.24–0.46)*** 0.31 (0.20–0.46)***
apoAI/apoB 2.45 (2.25–3.90) 1.74 (0.90–3.36)** 1.96 (1.09–3.15)** 1.86 (0.90–3.36)**
apoAI/apoCIII 57 (42–62) 33 (16–64)** 43 (26–54)** 39 (16–64)**
Values are expressed as median (min–max): * P \ 0.05, ** P \ 0.01, *** P \ 0.001 versus the reference group,  P \ 0.05 versus the Tx
patients
Table 1 Clinical and routine laboratory parameters in the reference group and post-renal transplant patients (Tx)
Reference group
(n = 15)
Tx patients with statin
(n = 25)




Age (years) 44 (22–50) 51 (20–66) 38 (19–61) 44 (19–66)
Gender (male/female) 7 M, 8F 13 M, 12F 15 M, 17F 28 M, 29F
BMI (kg/m2) 21.0 (18.5–24.7)* 25.6 (20.1–35.2)* 22.9 (20.4–27.4) 24.3 (19.9–35.2)*
eGFR M (mL/min/1.73 m2) 120 (103–127) 81 (60–131) 84 (62–143) 81 (60–143)
eGFR F (mL/min/1.73 m2) 108 (98–120) 68 (51–91) 71 (51–122) 69 (51–122)
Time after transplantation (years) – 5.8 (1–15) 4.36 (1–13) 5.1 (1–15)
Creatinine (lmol/L) 74 (62–99) 106 (61.9–159.1) 106 (61.9–141.4) 106 (61.9–159.1)
Albumin (g/L) 44.1 (42.2–47.9) 43.0 (41.1–48.2) 43.7 (42.0–48.3) 43.2 (41.1–48.3)
BMI body mass index, eGFR estimated glomerular filtration rate, M male, F female
Values are expressed as median (min–max): * P \ 0.05, ** P \ 0.01 versus reference group
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positive association with LDL-C (b = 0.466, P = 0.019),
and a significant negative association with apoAI (b =
-0.449, P = 0.039).
Dichotomized multiple ridge stepwise forward regression
analysis for all Tx patients showed that LCAT (R2 = 0.433)
was significantly positively associated with apoAIInonB
(b = 0.292, P = 0.017), significantly negatively associated
with apoAI (b = -0.249, P = 0.049) and TG (b = -0.395,
P = 0.0006), and non-significantly positively associated
with apoCIIInonB (b = 0.205, P = 0.056) and apoB:AII
(b = 0.221, P = 0.058).
Discussion
Cardiovascular disease is the main cause of mortality in renal
transplantation and the second cause of graft loss and death
with functioning graft [13]. Reverse kidney renal failure after
renal transplantation is associated with various types of
metabolic dysfunctions, but lipid and lipoprotein abnor-
malities appear to progress in Tx patients as a consequence of
immunosuppressive therapy [13]. The Tx patients in the
present study received cyclosporine A (CSA) (60 %) or
prograf (40 %), and additionally MyFortic, Azatioprine, and
CelCept. Because these patients had worse lipid profiles,
they received statin therapy. However, the Tx patients
without statin therapy received prograf (60 %) or cyclo-
sporine A (40 %), and additionally MyFortic, Azatioprine,
and CellCept. These patients had better lipid profiles and did
not receive anti-lipidemic therapy. The stepwise switch from
CSA to MyFortic was safe and mostly successful, and had
beneficial effects on blood pressure, glomerular hemody-
namics, and lipid profiles. Beneficial trends were already
presented after withdrawal of CSA [14].








LCAT CETP LCAT CETP LCAT CETP
R R R
TG -0.538** 0.035 -0.183 -0.130 -0.176 0.002
HDL-C 0.155 -0.528** 0.059 0.192 -0.113 -0.070
apoB -0.149 0.240 0.389* 0.062 0.405** 0.096
apoCIII 0.333 0.079 0.357* 0.039 0.529*** -0.054
apoCIIInonB 0.508* 0.241 0.250 0.148 0.426*** 0.041
HDL-C/apoAI 0.036 -0.529** 0.054 0.547** -0.136 0.088
apoAI/apoB 0.041 -0.365* -0.235 -0.151 -0.305* -0.179
apoAI/apoCIII -0.247 -0.057 -0.158 -0.123 -0.474*** -0.023
hsCRP 0.036 -0.097 0.147 0.137 0.275* 0.039
* P \ 0.05, ** P \ 0.01, *** P \ 0.001
Table 4 Multiple ridge forward regression between mass of LCAT and lipids, lipoproteins in all Tx patients, and with and without statin
therapy, and all Tx patients dichotomized
All Tx patients
(n = 57; R2 = 0.321)
Tx patients with statin
(n = 32; R2 = 0.261)
Tx patients
without statin
(n = 25; R2 = 0.372)
Tx patients without statin
n = 27 high HDL-C
(R2 = 0.394)
All Tx patients dichoto
mized data
(n = 57; R2 = 0.433)
b P b P b P b P b P
apoAI -0.449 0.038 -0.249 0.049





TG -0.306 0.007 -0.415 0.041 -0.492 0.002 -0.395 0.0006
LDL-C 0.466 0.019
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The in vivo results of the present study showed that Tx
patients with and without statin therapy had moderate
dyslipidemia, dyslipoproteinemia, and atherogenic lipid
and lipoprotein ratios, decreased LCAT mass, and slightly
increased hsCRP, but no CETP activity. Spearman’s cor-
relation test between lipids and lipoproteins and LCAT or
CETP activity indicated that in Tx patients with statin,
moderate hypercholesterolemia, hypertriglyceridemia, and
increased TRLs (apoB:CIII and apoB:AII), LCAT
was significantly positively correlated with apoCIII and
significantly negatively with TG levels. Simultaneously,
CETP was significantly negatively correlated with apoAI/
apoB, and HDL-C/apoAI and HDL-C composition. In Tx
patients without statin, there were lower concentration of
TRLs (lower apoB:CIII but not apoB:AII) and beneficial
lipid and lipoprotein ratios than Tx patients with statin, but
worse than controls; LCAT was significantly positively
correlated with apoB and apoCIII. At the same time, CETP
was significantly positively correlated with HDL-C/apoAI
composition of HDL. In multiple ridge stepwise forward
regression, the Tx patients showed that immunosuppressive
therapy can cause disturbed lipoprotein composition of
HDL and TRLs [15, 16]. Tx patients with higher TG and
TRLs levels and disturbed composition of apoCIII, apoAI,
apoAII, and TG in HDL can decrease LCAT. However,
Tx patients without statin and with lower TG but higher
HDL-C and disturbed lipoprotein composition of ApoAI
and apoAII in HDL particle can decrease LCAT and
increase LDL cholesterol. Moreover, increased TG and
LDL-C and hsCRP together with disturbed lipoproteins
composition can aggravate renal graft and accelerate ath-
erosclerosis and chronic heart disease. The authors of the
present study have shown previously that Tx patients with
hypertriglyceridemia have HDL particles remodeled by
subclass distribution into smaller-sized particles, that the
concentration of HDL particles decreased, and that the
HDL-C/apoAI ratio seemed to be a good marker of HDL
subclass distribution into smaller size particles [15, 16].
The presented in vivo results of Tx patients suggest that
the inhibition or activation of LCAT is due, in part, to
HDL-associated lipoprotein. HDL and TRLs composition
can contribute to the decrease or increase in LCAT and can
modulate all concentrations of TG and/or LDL-C in serum
of Tx patients.
Castellani et al. [17] have reported that the function of
apoAII is to regulate the metabolism of TRLs, with HDL
serving as a pool of apoAII, the same as with the apoC
apolipoproteins that is transferred to the TRLs; however,
the function of apoAII remains unknown. The re-arrange-
ment in HDL composition, size, and function may be of
benefit to the anti-atherogenic HDL particles. LCAT
reaction requires not only disorder in the HDL surface, but
also specific interaction between the partners [such as
apoAI, LCAT, phosphatidylcholine (PCs and cholesterol)]
[18]. ApoAII on spherical HDLs: (1) stabilizes the lipo-
proteins against chemical or thermal denaturation,
(2) counteracts the anti-atherogenic effects of apoAI, and
(3) decelerates both the denaturation and metabolic
remodeling of spherical HDL [18]. Moderate structural
disorder accelerates the metabolic remodeling of HDLs,
which may benefit the HDL function in cholesterol
removal [18]. It has been suggested that apoCIII regulates
LCAT activity indirectly through apolipoprotein that acti-
vates LCAT [19]. Cho et al. [20] demonstrated that in vitro
LCAT activity decreased in response to increased apoCIII
content in rHDL and that this occurred in a dose-dependent
manner. This decreased ability of rHDL-containing apoCIII to
activate LCAT shows that LCAT exhibits 4–5 % LCAT
activation ability, while apoAI-rHDL exhibits 100 % reaction
rates [21].
Patients with low HDL-C displayed marked changes in
their HDL composition and subclass distributions. Larger
HDL2 particles, as well as HDL mean particle size, are
reduced in patients with low HDL-C. Small, dense HDL3
particle subclasses have more capacity to protect LDL
against oxidation than large, light HDL2 particles. There-
fore, the low susceptibility of HDL to oxidation in the low
HDL-C patients may be due to compositional changes
specifically in the HDL2 subclass [22]. It has been docu-
mented that in hypercholesterolemic patients, LCAT
activity was low while CETP activity was high, which was
associated with an increased plasma TC level in these
patients. The higher the TC levels, the particle size of HDL
subclasses has a tendency to be smaller, which suggests
that the elevated TC blocked the maturation of HDL sub-
classes metabolism and impeded the efficiency of RCT.
The net effect of CETP action on HDL is depletion of CE
and enrichment with TG, with an overall net reduction in
the size of the particles [23]. Bailey et al. [24] have pro-
vided a biochemical basis for the nascent HDL remodeling
pathway that involves plasma apoB-containing lipoprotein
and plasma phospholipid transfer protein (PLTP). The free
cholesterol content of the model nascent HDL pool was
transferred to plasma apoB, which was then redistributed to
HDL for esterification by LCAT. Subsequently, CEs were
transferred back to plasma apoB by CETP. Simultaneously,
PLTP mediated the depletion of the phospholipids content
of nascent HDL, leading to the incorporation of lipid-poor
apoAI into the plasma resident HDL pool, or conversion to
preb1–LpAI.
Bailey et al. also reported that the remodeling of the
HDL resident pool by CETP, hepatic triglyceride lipase
(H-TGL), and PLTP contributes to the generation of
preb1-LpAI or lipid-free apoAI. Importantly, this gives rise
to questions regarding the stability and structural integrity
of the nascent particles within the plasma environment, the
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123
significance of which deserves further investigation [24].
The results of the present study suggest that increased
HDL-C does not always protect against cardiovascular
disease and can sometimes be associated with increased
coronary events [25].
Conclusion
The results suggest that inhibition or activation of LCAT is
due, in part, to HDL-associated lipoprotein. Lipoprotein
composition of apoAI, apoAIInonB, and apoCIIInonB in
HDL particle and apoB:AII (TRLs) can contribute to decrease
LCAT in Tx patients. Tx patients without statin and with
lower TG but higher HDL-C, and disturbed lipoprotein
composition of ApoAI and apoAII in HDL particle can
decrease LCAT, increase LDL cholesterol, aggravate renal
graft, and accelerate atherosclerosis and chronic heart disease.
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